Due to high demand, the vaccination programme began to be hit with supply issues; exports of the Oxford–AstraZeneca vaccine were suspended to meet domestic demand, there have been shortages of the raw materials required to manufacture vaccines domestically, while hesitancy and a lack of knowledge among poorer, rural communities has also impacted the programme.
